Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) Invested Capital (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Invested Capital readings, the most recent being $11.4 million for Q4 2023.

  • On a quarterly basis, Invested Capital rose 111.13% to $11.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $11.4 million, a 111.13% increase, with the full-year FY2023 number at $11.4 million, up 111.13% from a year prior.
  • Invested Capital hit $11.4 million in Q4 2023 for Elicio Therapeutics, down from $13.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $92.4 million in Q1 2021 to a low of -$109.9 million in Q1 2023.
  • Median Invested Capital over the past 4 years was -$56.1 million (2020), compared with a mean of -$31.4 million.
  • Biggest five-year swings in Invested Capital: soared 401.35% in 2021 and later crashed 248.34% in 2022.
  • Elicio Therapeutics' Invested Capital stood at -$90.4 million in 2020, then rose by 17.92% to -$74.2 million in 2021, then crashed by 37.58% to -$102.1 million in 2022, then soared by 111.13% to $11.4 million in 2023.
  • The last three reported values for Invested Capital were $11.4 million (Q4 2023), $13.3 million (Q3 2023), and $23.6 million (Q2 2023) per Business Quant data.